English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Objective  Mutations in dysferlin (DYSF), a Ca 2+ ‐sensitive ferlin family protein important for membrane repair, vesicle trafficking, and T‐tubule function, cause Miyoshi myopathy, limb‐girdle muscular dystrophy type 2B, and distal myopathy. More than 330 pathogenic  DYSF  mutations have been identified within exons or near exon–intron junctions. In ~17% of patients who lack normal DYSF, only a single disease‐causing mutation has been identified. We studied one family with one known mutant allele to identify both the second underlying genetic defect and potential therapeutic approaches.    Methods  We sequenced the full  DYSF  cDNA and investigated antisense oligonucleotides (AONs) as a tool to modify splicing of the mRNA transcripts in order to process out mutant sequences.    Results  We identified a novel pseudoexon between exons 44 and 45, (pseudoexon 44.1, PE44.1), which inserts an additional 177 nucleotides into the mRNA and 59 amino acids within the conserved C2F domain of the DYSF protein. Two unrelated dysferlinopathy patients were also found to carry this mutation. Using AONs targeting PE44.1, we blocked the abnormal splicing event, yielding normal, full‐length  DYSF  mRNA, and increased DYSF protein expression.    Interpretation  This is the first report of a deep intronic mutation in  DYSF  that alters mRNA splicing to include a mutant peptide fragment within a key  DYSF  domain. We report that AON‐mediated exon‐skipping restores production of normal, full‐length  DYSF  in patients' cells in vitro, offering hope that this approach will be therapeutic in this genetic context, and providing a foundation for AON therapeutics targeting other pathogenic  DYSF  alleles.

A novel dysferlin mutant pseudoexon bypassed with antisense oligonucleotides